Jueling Mingmu decoction combined with ranibizumab for retinal vein occlusion induced macular edema: A randomized controlled clinical trial
Abstract
Background/aims: To investigate the efficacy of a combined treatment approach using Jueling Mingmu Decoction and ranibizumab in managing macular edema (ME) associated with retinal vein occlusion (RVO).
Methods: This prospective, randomized, controlled, outcome assessor-blinded superiority trial involved 111 patients with treatment-naïve RVO and ME, including 53 patients assigned to the ranibizumab monotherapy group and 58 to the combination therapy group. Participants were randomly assigned to receive either intravitreal injections of 0.5 mg ranibizumab alone (monotherapy group) or combined with daily consumption of Jueling Mingmu Decoction (combination group). Primary outcomes included the number of intravitreal injections administered over 48 weeks. Secondary outcomes included changes in best-corrected visual acuity (BCVA) and central subfield fovea thickness (CST).
Results: 99 patients (89.2%) completed the 48-week follow-up, including 46 of 53 patients (86.8%) in the monotherapy group and 53 of 58 patients (91.4%) in the combination group. The monotherapy group received an average of 4.35 ± 1.73 injections, while the combination group received 4.64 ± 1.92 injections (P = 0.471), with no significant difference between the groups. BCVA improved significantly in both groups, with the combination group showing a greater improvement at 48 weeks in patients with branch RVO (BRVO) compared to the monotherapy group (P = 0.031). CST decreased significantly in both groups, with…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 111 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.